<--Back to project organisation page

Work package 4

Compounds from WP1, WP2, WP3 will be further analysed by groups oriented to characterization and validation of PKs as drug targets, especially as regards structural and functional studies. These laboratories will give the feedback of bio-activity to the screening/synthesis laboratories (WP1, WP2, WP3).

It is essential to get the feedback information from biological tests as soon as possible, and therefore the bioactivity testing should be done parallel to the synthesis work.

Synthesis of pure chemicals takes a relatively long period of time as compared to make tests. New bioactivity tests will be developed and this development also requires long time. These are done in parallel.

Groups in WP 4:
  University of Dundee
MRC Protein Phosphorylation Unit, MSI/WTB Complex
    Prof. Sir Philip Cohen
  Venetian Institute for Molecular Medicine (VIMM) and University of Padova, Departments of Biological Chemistry and Organic Chemistry
    Prof. Lorenzo A. Pinna
    Prof. Giuseppe Zanotti
  Cancer Research UK
London Research Institute, Protein Phosphorylation and Structural Biology Laboratories
    Prof. Peter J. Parker
  University of Oxford
Laboratory of Molecular Biophysics
    Prof. Dame Louise N. Johnson
    Dr. Jane A. Endicott
    Dr. Jim McDonnell
    Dr. Martin E. M. Noble
  Innsbruck Medical University
    Prof. Johann Hofmann
  University of Milano-Bicocca
    Dr. Carlo Gambacorti-Passerini
Dr. Rosalind Gunby

  ProQinase/KTB Tumourforschungs GmbH
    Dr. Michael Kubbutat
  Pepscan Systems BV
    Dr. Peter van Dijken
    Dr. Jos Joore